PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase II Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

PDS Biotechnology Corporation announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor refractory arm of the NCI-Led Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV-associated cancers.